Warfarin and amoxicillin/clavulanate drug interaction

被引:32
作者
Davydov, L
Yermolnik, M
Cuni, LJ
机构
[1] St Johns Episcopal hosp, Dept Pharm, Far Rockaway, NY USA
[2] Long Isl Univ, Arnold & Marie Schwartz Coll Pharm & Hlth Sci, Brooklyn, NY USA
[3] SUNY Brooklyn, Brooklyn, NY USA
关键词
amoxicillin/clavulanate potassium; international normalized ratio; warfarin;
D O I
10.1345/aph.1C243
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
OBJECTIVE: To report a case of warfarin-amoxicillin/clavulanate potassium (AM/CL) interaction resulting in an elevated international normalized ratio (INR) and hematuria. CASE SUMMARY: A 58-year-old Hawaiian/Asian/European woman developed an elevated INR and microscopic hematuria as a result of a drug-drug interaction between warfarin and AM/CL. DISCUSSION: Our report of an increased INR with bleeding complications as a result of an interaction between warfarin and AM/CL is consistent with those in the literature. Although the mechanism for this interaction is not fully known, it is suspected that a decrease in vitamin K-producing gut flora with resulting vitamin K deficiency would be the most likely contributing factor. An objective causality assessment revealed that this adverse drug event as a result of the warfarin and AM/CL interaction was possible. CONCLUSIONS: An increased INR secondary to warfarin interactions with various antibacterial agents is a known phenomenon. An increased awareness of warfarin-AM/CL interaction and appropriate monitoring are essential to control the INR levels and prevent bleeding complications.
引用
收藏
页码:367 / 370
页数:4
相关论文
共 22 条
[1]   Amoxicillin-related postextraction bleeding in an anticoagulated patient with tranexamic acid rinses [J].
Bandrowsky, T ;
Vorono, AA ;
Borris, TJ ;
Marcantoni, HW .
ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY AND ENDODONTOLOGY, 1996, 82 (06) :610-612
[2]   Changes in plasma protein binding have little clinical relevance [J].
Benet, LZ ;
Hoener, BA .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 71 (03) :115-121
[3]  
*BRIS MYERS SQ, 2001, PACK INS COUM WARF
[4]  
CONLY J, 1994, CLIN INVEST MED, V17, P531
[5]   Clinically important drug interactions with anticoagulants - An update [J].
Harder, S ;
Thurmann, P .
CLINICAL PHARMACOKINETICS, 1996, 30 (06) :416-444
[6]   Oral anticoagulants: Mechanism of action, clinical effectiveness, and optimal therapeutic range [J].
Hirsh, J ;
Dalen, JE ;
Anderson, DR ;
Poller, L ;
Bussey, H ;
Ansell, J ;
Deykin, D .
CHEST, 2001, 119 (01) :8S-21S
[7]   Interactions between herbal medicines and prescribed drugs - A systematic review [J].
Izzo, AA ;
Ernst, E .
DRUGS, 2001, 61 (15) :2163-2175
[8]  
KELLY JG, 1979, CLIN PHARMACOKINET, V4, P1, DOI 10.2165/00003088-197904010-00001
[9]   WARFARIN - STEREOCHEMICAL ASPECTS OF ITS METABOLISM AND INTERACTION WITH PHENYLBUTAZONE [J].
LEWIS, RJ ;
TRAGER, WF ;
CHAN, KK ;
BRECKENRIDGE, A ;
ORME, M ;
ROLAND, M ;
SCHARY, W .
JOURNAL OF CLINICAL INVESTIGATION, 1974, 53 (06) :1607-1617
[10]   A METHOD FOR ESTIMATING THE PROBABILITY OF ADVERSE DRUG-REACTIONS [J].
NARANJO, CA ;
BUSTO, U ;
SELLERS, EM ;
SANDOR, P ;
RUIZ, I ;
ROBERTS, EA ;
JANECEK, E ;
DOMECQ, C ;
GREENBLATT, DJ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1981, 30 (02) :239-245